Hainan Shuangcheng Pharmaceut (002693) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hainan Shuangcheng Pharmaceut (002693) has a cash flow conversion efficiency ratio of 0.083x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥33.67 Million ≈ $4.93 Million USD) by net assets (CN¥404.35 Million ≈ $59.17 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Hainan Shuangcheng Pharmaceut liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Hainan Shuangcheng Pharmaceut - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Hainan Shuangcheng Pharmaceut's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hainan Shuangcheng Pharmaceut Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hainan Shuangcheng Pharmaceut ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PDS Limited
NSE:PDSL
|
-0.080x |
|
Beijing Career International Co Ltd
SHE:300662
|
0.059x |
|
Indigo Paints Limited
NSE:INDIGOPNTS
|
0.027x |
|
Duratec Ltd
AU:DUR
|
0.111x |
|
Serve Robotics Inc. Common Stock
NASDAQ:SERV
|
-0.130x |
|
Shenzhen Asiantime International Construction Co Ltd
SHE:002811
|
0.071x |
|
Viyash Scientific Limited
NSE:SEQUENT
|
0.051x |
|
Gazit Globe Ltd
TA:GZT
|
0.007x |
Annual Cash Flow Conversion Efficiency for Hainan Shuangcheng Pharmaceut (2009–2025)
The table below shows the annual cash flow conversion efficiency of Hainan Shuangcheng Pharmaceut from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see 002693 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥420.53 Million ≈ $61.54 Million |
CN¥60.95 Million ≈ $8.92 Million |
0.145x | +246.12% |
| 2024-12-31 | CN¥411.61 Million ≈ $60.23 Million |
CN¥-40.83 Million ≈ $-5.97 Million |
-0.099x | -541.12% |
| 2023-12-31 | CN¥517.65 Million ≈ $75.75 Million |
CN¥11.64 Million ≈ $1.70 Million |
0.022x | -48.20% |
| 2022-12-31 | CN¥580.94 Million ≈ $85.01 Million |
CN¥25.22 Million ≈ $3.69 Million |
0.043x | +4.45% |
| 2021-12-31 | CN¥566.75 Million ≈ $82.93 Million |
CN¥23.55 Million ≈ $3.45 Million |
0.042x | +336.77% |
| 2020-12-31 | CN¥598.31 Million ≈ $87.55 Million |
CN¥-10.50 Million ≈ $-1.54 Million |
-0.018x | -117.88% |
| 2019-12-31 | CN¥678.26 Million ≈ $99.25 Million |
CN¥66.58 Million ≈ $9.74 Million |
0.098x | +40.36% |
| 2018-12-31 | CN¥669.69 Million ≈ $98.00 Million |
CN¥46.84 Million ≈ $6.85 Million |
0.070x | +336.39% |
| 2017-12-31 | CN¥761.71 Million ≈ $111.46 Million |
CN¥-22.54 Million ≈ $-3.30 Million |
-0.030x | -142.35% |
| 2016-12-31 | CN¥553.13 Million ≈ $80.94 Million |
CN¥38.65 Million ≈ $5.66 Million |
0.070x | +40.17% |
| 2015-12-31 | CN¥927.61 Million ≈ $135.74 Million |
CN¥46.24 Million ≈ $6.77 Million |
0.050x | -12.67% |
| 2014-12-31 | CN¥893.55 Million ≈ $130.75 Million |
CN¥51.00 Million ≈ $7.46 Million |
0.057x | -11.95% |
| 2013-12-31 | CN¥870.62 Million ≈ $127.40 Million |
CN¥56.43 Million ≈ $8.26 Million |
0.065x | -31.65% |
| 2012-12-31 | CN¥845.85 Million ≈ $123.77 Million |
CN¥80.22 Million ≈ $11.74 Million |
0.095x | -67.23% |
| 2011-12-31 | CN¥228.23 Million ≈ $33.40 Million |
CN¥66.05 Million ≈ $9.67 Million |
0.289x | -17.45% |
| 2010-12-31 | CN¥157.82 Million ≈ $23.09 Million |
CN¥55.33 Million ≈ $8.10 Million |
0.351x | -38.27% |
| 2009-12-31 | CN¥77.95 Million ≈ $11.41 Million |
CN¥44.27 Million ≈ $6.48 Million |
0.568x | -- |
About Hainan Shuangcheng Pharmaceut
Hainan Shuangcheng Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical injections, solid preparations, and raw materials in China and internationally. The company offers products for oncology and immune, alimentary canal, heart and cerebral, and vessels and metabolism. It also provides Bivalirudin, Epitifibatide, and Thymalfaxin for injection; Pre… Read more